The landscape of dementia analysis has developed dramatically with the advent of complex biomarkers, including amyloid PET scans, tau imaging, and blood-primarily based exams which will detect Alzheimer's pathology decades before signs emerge. Even though these technological advancements characterize remarkable progress in comprehending neurodegene